Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension

For OM5/LOV111858 - Inclusion Criteria: * Men and women ages 18-79 years, inclusive * Triglyceride levels between 500 mg/dL and \<1300 mg/dL * Body mass index between 25 and 43 kg/m2 * Willingness to follow a low-saturated fat diet during the study period and maintain current physical activity level * Normally active and in good health on the basis of medical history, brief physical examination, electrocardiogram, and routine laboratory tests * Provide written informed consent and authorization for protected health information disclosure Exclusion Criteria: * Sensitivity to fibrate drugs or omega-3 fatty acids * Lipoprotein lipase impairment or apo C-2 deficiency or Type III hyperlipidemia * History of pancreatitis * Recent history of certain kidney, liver, lung, or gastrointestinal disease or cancer (except non-melanoma skin cancer) * Poorly controlled diabetes mellitus * Type 1 diabetes * Pregnant or lactating females. Women of childbearing potential who are not using a medically approved method of contraception. * Use of certain types of hormones, anticonvulsant drugs, immunologic drugs, antibiotic, antifungal and antiviral drugs, and cardiac drugs * Use of isotretinoin (Accutane) * Use of warfarin (Coumadin) For OM5X/LOV111859 - Subjects were included in the study if they met the following criteria: 1. Satisfied all inclusion and exclusion criteria prior to and throughout the previous OM5 study or had a corresponding approved protocol deviation 2. Successfully completed the previous OM5 double-blind study to Week 8 3. Provided written informed consent on or before the Week 8 clinic visit of the OM5 double-blind study (i.e., Visit 1X of the OM5X extension study)